Bionomics (BNO), an Australian listed clinical stage biopharmaceutical company announced on Wednesday that it has partnered with EmpathBio, a subsidiary of the largest private psychedelic company, ATAI Life Sciences. Through the new partnership, the companies will explore a combination drug treatment regimen using EmpathBio’s MDMA derivative, EMP-01, and Bionomics’ lead drug candidate, BNC210. The regimen…